AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings & Note 5
Latest, Q2 2026
291
Period ended Jun 30, 2026
Change on a year earlier
-64.6%
823 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
37
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 291 | -64.6% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 744 | +200.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | -3,149 | +1,413.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,680 | +3,168.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 823 | -12.2% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2025 | Mar 31, 2025 | 248 | +51.2% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | -208 | -341.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 82 | +24.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 937 | +234.6% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 164 | +9.3% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 86 | +62.3% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 66 | +65.0% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 280 | +26.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 150 | +3.4% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 53 | -110.1% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 40 | -90.0% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 222 | +68.2% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 145 | -21.6% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | -527 | -18.9% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 402 | +793.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 132 | -84.5% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 185 | – | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | -650 | -567.6% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 45 | – | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 853 | +837.4% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | -100.0% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 139 | -53.7% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 0 | -100.0% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 91 | – | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 155 | +124.6% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 300 | +180.4% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 55 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 0 | -100.0% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 69 | – | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 107 | +167.5% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 0 | -100.0% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 15 | -78.6% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 0 | -100.0% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2016 | Dec 31, 2016 | 40 | -140.0% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 80 | – | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 70 | +204.3% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 10 | -92.1% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | -100 | – | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2015 | Sep 30, 2015 | 0 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 23 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 127 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up acquired ipr&d and milestones expense — upfront & collaboration charges ($m)
Cite this data
StockData. (2026). AbbVie Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/iprd_upfront_exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.